5 5 correctly predicted forecasts
Send me real-time posts from this site at my email

Watchlist Update: 11-14-2018 - Sangamo - SGMO - Analyst Comments

Sangamo downgraded to Neutral from Overweight at JPMorgan

JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics to Neutral and lowered his price target for the shares to $11 from $35. The analyst sees a lack of catalysts following last week's Q3 results.

Read more at: 
https://thefly.com/landingPage...

(Source theFly)

* This stock has been on our trading list for a while now. Will continue to look for trades in this name. *

** We have some of this one and admit currently taking a beating. Tech and Biotech have been a bad place to be. **


$SGMO, Sangamo Therapeutics, Inc. / H1


Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or posts.